Altimmune Inc expected to post a loss of 14 cents a share - Earnings Preview

Altimmune

10/08/2026 14:51

Altimmune Inc ALT.OQ ALT.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 for the period ending June 30 2026

​LSEG's mean analyst estimate for Altimmune Inc is for a loss of 14 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had fallen by about 0.2% in the last three months. ​
Wall Street's median 12-month price target for Altimmune Inc is $19.00, about 516.9% above its last closing price of $3.08
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.25
-0.25
-0.18
Beat
26.6
Dec. 31 2026
-0.24
-0.24
-0.27
Missed
-11.3
Sep. 30 2025
-0.28
-0.28
-0.21
Beat
25.4​
Jun. 30 2025
-0.33
-0.32
-0.27
Beat
16.4
​​Mar. 31 2025
-0.37
-0.36
-0.26
Beat
28.4
Dec. 31 2024
-0.34
-0.33
-0.33
Met
-0.8​
Sep. 30 2024
-0.38
-0.35
-0.32
Beat
9.6
Jun. 30 2024
-0.34
-0.34
-0.35
Missed
-2.6
This summary was machine generated August 10 at 13:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)